Table 2.
Antagonists targeting CCR2-CCL2 axis.
| Product | Developer | Stage | Target | Indications | Status | References/Trial ID |
|---|---|---|---|---|---|---|
| AZD2423 | AstraZeneca | II | CCR2 | Chronic obstructive pulmonary disease (COPD) | Inactive | NCT01215279 |
| BMS-687681 | Bristol-Myers Squibb | Pre | CCR2, CCR5 | Cancer | Active | (174) |
| BMS-741672 | Bristol-Myers Squibb | II | CCR2 | Type II diabetes | Inactive | NCT00699790 |
| BMS-813160 | Bristol-Myers Squibb | I/II | CCR2, CCR5 | Pancreatic cancer, Colorectal cancer, Liver cancer, NSCL | Active | NCT03184870; NCT04123379 |
| BMS-813160 | Bristol-Myers Squibb | II | CCR2, CCR5 | Type II diabetes | Active, Inactive | NCT01752985 |
| CCX140 | ChemoCentryx, Vifor Pharma | II | CCR2 | Type II diabetes, Fibrosis | Active | (175), NCT01447147. |
| CCX872 | ChemoCentryx | I/II | CCR2 | Pancreatic cancer | Active, Inactive | NCT02345408, NCT03778879 |
| Cenicriviroc | Takeda Pharmaceuticals, Dong-A Pharma, Tobira Therapeutics (AbbVie) | II | CCR2, CCR5 | HIV | Inactive | (176) |
| Cenicriviroc | Takeda Pharmaceuticals, Dong-A Pharma, Tobira Therapeutics (AbbVie) | III | CCR2, CCR5 | NASH, HIV, COVID19 | Active, Inactive | NCT03028740 |
| CNTX-6970 | Centrexion Therapeutics | I | CCR2 | Pain | Active | NCT03787004 |
| INCB8696 | Incyte | I | CCR2 | MS | Inactive | (177) |
| INCB3344 | Incyte | Pre | CCR2 | MS, RA | Inactive | (178) |
| INCB3284 | Incyte | Pre | CCR2 | Undefined inflammation | Inactive | (179) |
| INCB10820 | Incyte, Pfizer | Pre | CCR2, CCR5 | Autoimmune diseases | Inactive | (180) |
| JNJ-17166864 | Johnson & Johnson | II | CCR2 | Allergic rhinitis | Inactive | NCT00604123 |
| JNJ-27141491 | Johnson & Johnson | Pre | CCR2 | MS | Inactive | (181) |
| JNJ-41443532 | Johnson & Johnson | II | CCR2 | Type II diabetes | Inactive | NCT01230749 |
| MK-0812 | Merck & Co. | II | CCR2 | RA, MS | Inactive | NCT00239655 |
| PF-04136309 | Incyte, Pfizer | II | CCR2 | Pancreatic cancer, Arthritic pain, Chronic hepatitis | Inactive | NCT02732938; NCT00689273; NCT01226797 |
| PF-04634817 | Pfizer | II | CCR2, CCR5 | Type II diabetes | Inactive | NCT01712061 |
| RAP-103 | Creative Bio-Peptides | Pre | CCR2, CCR5, CCR8 | Neurophathic Pain | Active | (182) |
| RO5234444 | Roche | Pre | CCR2 | Type II diabetes | Inactive | (183) |
| SSR150106 | Sanofi | II | CCR2 | RA | Inactive | NCT00545454 |
| Tropifexor+Cenicriviroc | Allergan (AbbVie), Novartis | II | CCR2, CCR5, FXR | NASH | Active | CLJC242A2201J; NCT03517540 |
| WXSH0213 | WuXi AppTec, Zhongsheng Pharmaceuticals | Pre | CCR2, CCR5 | NASH | Active | (184) |
| Bindarit | Angelini | II | CCL2 | Type II diabetes, Atherosclerosis | Inactive | NCT01109212 |
| NOX-E36 | NOXXON Pharma AG | II | CCL2 | Type II diabetes | Inactive | NCT01547897 |
| NOX-E36 | NOXXON Pharma AG | Pre | CCL2 | Liver fibrosis | Inactive | (185) |